Financial Performance - HeartSciences Inc. reported financial results for the quarter ended October 31, 2025, with a focus on operational performance and business updates[7]. - The press release detailing the financial results is included as Exhibit 99.1 in the Current Report[9]. Company Classification - The company is classified as an emerging growth company under the Securities Act of 1933[6].

Southlake, TX, Dec. 15, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today reported financial results for its fiscal second quarter ended October 31, 2025 (“FQ2 2026”) and provided a business update. Second Quarter and Recent Highlights During the second quarter and subsequent period, the Com ...

Financial Position - HeartSciences reported stockholders' equity of $1,786,689 as of January 31, 2025, which is below the Nasdaq minimum requirement of $2.5 million[177]. - As of the date of the report, the Company has received approximately $1.9 million in net proceeds from the Streeterville Note[182]. - Cash and cash equivalents increased to approximately $2.0 million as of October 31, 2025, up from $1.1 million as of April 30, 2025[208]. - The company expects existing cash to be insufficient to fund operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern[203]. Revenue and Expenses - HeartSciences expects to generate revenues from installation fees, SaaS usage fees, and fees associated with AI-ECG algorithms through the MyoVista Insights platform[172]. - Revenue for the three and six months ended October 31, 2025, was $2,000 and $4,000, respectively, compared to no revenue for the same periods in 2024[196]. - Research and development expenses decreased by $473,000, or 39%, for the three months and $700,000, or 29%, for the six months ended October 31, 2025, compared to the same periods in 2024[197]. - Selling, general, and administrative expenses increased by $562,000, or 71%, for the three months and $589,000, or 36%, for the six months ended October 31, 2025, compared to the same periods in 2024[198]. - Interest expense rose to $280,000 and $463,000 for the three and six months ended October 31, 2025, representing increases of 137% and 231%, respectively, compared to the same periods in 2024[199]. - The company incurred a net loss of $4.4 million for the six months ended October 31, 2025, with an accumulated deficit of $80.5 million[202]. - Net cash used in operating activities was $4.3 million for the six months ended October 31, 2025, primarily due to the net loss[211]. - Net cash provided by financing activities was $5.2 million during the six months ended October 31, 2025, primarily from the issuance of Series D Preferred Stock and warrants[212]. Funding and Stock Issuance - The Company has issued 1,912,383 Units consisting of Series D Preferred Stock and Warrants for gross proceeds of approximately $6.7 million[186]. - The Series D Preferred Stock Offering has a maximum offering amount of $15.0 million, with each Unit priced at $3.50[183]. - The company issued 1,912,383 Units for gross proceeds of approximately $6.7 million during the six months ended October 31, 2025[204]. Regulatory and Product Development - The MyoVista wavECG device was submitted to the FDA for 510(k) premarket clearance in December 2025[175]. - The Company received a "Breakthrough Device" designation from the FDA for its aortic stenosis ECG algorithm in June 2025[181]. - The Company plans to separate FDA submissions for the MyoVista wavECG device and the impaired cardiac relaxation AI-ECG algorithm due to updated clinical standards[173]. Operational Challenges - HeartSciences has experienced recurring losses and negative cash flows from operations, raising substantial doubt about its ability to continue as a going concern[176].

Southlake, TX, Dec. 15, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing the use of ECG/EKGs through the integration of artificial intelligence (“AI”), today announced it has submitted its MyoVista® wavECG™ device to the U.S. Food and Drug Administration (“FDA”) for 510(k) premarket clearance. The MyoVista wavECG device is designed to provide conventional ECG functionality while serving as a pl ...

Version 1.1 Designed to Provide Best Usability of any ECG SystemSouthlake, TX, Dec. 11, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing the use of ECG/EKGs through the integration of artificial intelligence (“AI”), today announced the commercial release of MyoVista Insights™ version 1.1, a major update that is built to provide the most usable ECG system and enhances clinical interpretation cap ...

Core Viewpoint - HeartSciences Inc. (HSCS) has shown a downtrend recently, with an 8.3% loss over the past two weeks, but a hammer chart pattern suggests a potential trend reversal as buying interest may be emerging [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out, suggesting that selling pressure may be subsiding [2][5]. - This pattern forms when a stock opens lower, makes a new low, but then closes near or above the opening price, indicating that bulls may be gaining control [4][5]. - Hammer candles can appear on various timeframes and are utilized by both short-term and long-term investors [5]. Fundamental Analysis - There is a strong consensus among Wall Street analysts to raise earnings estimates for HSCS, which supports the bullish case for the stock [2][7]. - The consensus EPS estimate for the current year has increased by 57.4% over the last 30 days, indicating analysts' agreement on the company's improved earnings potential [8]. - HSCS holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10].

Financial Performance - HeartSciences Inc. reported financial results for the quarter ended July 31, 2025, with a focus on operational performance and business updates[7]. - The report does not include specific financial metrics or performance indicators, as the detailed results are provided in the press release[8]. Company Classification - The company is classified as an emerging growth company under the Securities Act of 1933[6]. Stock Information - A press release detailing the financial and operational results was issued on September 11, 2025[7]. - The company's common stock and warrants are traded on The Nasdaq Stock Market LLC under the symbols HSCS and HSCSW, respectively[5].

Core Insights - HeartSciences Inc. reported significant advancements in the first quarter of fiscal 2026, including the FDA Breakthrough Device Designation and the launch of MyoVista Insights, an AI-powered ECG management platform [2][5][8] Financial Performance - For FQ1 2026, HeartSciences reported no meaningful revenue, with approximately $2.8 million in cash and cash equivalents and $3.1 million in shareholders' equity as of July 31, 2025 [9][10] - The company raised an additional $0.8 million through a Reg A+ offering and converted $0.7 million of debt into equity, enhancing its financial position [9] Product Development - MyoVista Insights is a cloud-native software platform aimed at modernizing ECG management systems and facilitating access to AI-ECG algorithms without the need for new ECG devices [6][11] - The platform is designed to integrate with existing ECG hardware and clinical workflows, with CPT reimbursement codes approved by CMS to support AI-ECG adoption [6] - The MyoVista wavECG device is set to host AI-ECG algorithms and is on track for FDA 510(k) submission within the current calendar year [6] Regulatory and Market Position - The FDA granted Breakthrough Device designation for HeartSciences' aortic stenosis ECG algorithm, validating the company's AI-ECG opportunity [5][8] - The company plans to update its algorithms in response to new guidelines from the American Society of Echocardiography, which may enhance its commercial value [6] Intellectual Property - HeartSciences expanded its intellectual property portfolio, holding 44 granted patents worldwide, including a key U.S. patent for estimating echocardiographic parameters via ECG [7]

Financial Performance - Revenues for the three months ended July 31, 2025, were $2,000, with a cost of sales of $1,000, resulting in a gross margin of $1,000 [193]. - The Company incurred a net loss of $2.1 million for the period ended July 31, 2025, with an accumulated deficit of $78.2 million [198]. - Cash and cash equivalents increased to approximately $2.8 million as of July 31, 2025, up from $1.1 million as of April 30, 2025 [205]. - Net cash used in operating activities was $1.9 million during the three months ended July 31, 2025, primarily due to the net loss [207]. - Net cash provided by financing activities was $3.6 million during the three months ended July 31, 2025, primarily from the issuance of Series D Preferred Stock and warrants [209]. Research and Development - The company is focused on developing AI and innovative software technology to enhance the clinical usefulness of ECGs, aiming to provide modernized ECG solutions for a broader range of heart disease detection [155]. - Phase 1 of the MyoVista Insights Cloud Platform has been launched, with expected revenue from installation fees and SaaS-based usage fees, adopting a recurring subscription revenue model for AI-ECG algorithms [157]. - The company has been granted a foundational patent covering the estimation of echocardiography parameters indicative of heart function using an ECG in June 2025 [175]. - Research and development expenses decreased by $228,000, or 19%, to $997,000 for the three months ended July 31, 2025, primarily due to reduced cloud consulting costs [194]. Regulatory and Compliance - The company received FDA "Breakthrough Device" designation for its aortic stenosis ECG algorithm in June 2025 [176]. - The company plans to submit the MyoVista wavECG device for FDA clearance under the 510(k) pathway in calendar 2025 [170]. - The company aims for an FDA submission of a low-ejection fraction algorithm during the first half of calendar 2026 [170]. Capital and Financing - The company has entered into a Series D Preferred Stock offering with a maximum amount of $15.0 million, priced at $3.50 per unit [178]. - The Company issued 1,556,409 Units consisting of Series D Preferred Stock and Warrants for gross proceeds of approximately $5.4 million as of the date of the Quarterly Report [181]. - The Company expects to continue raising capital through the sale of additional equity securities, debt, or strategic partnerships to fund ongoing operations [204]. Operational Challenges - The company has experienced recurring losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern [172]. - As of January 31, 2025, the company's stockholders' equity was reported at $1,786,689, below the Nasdaq minimum requirement of $2.5 million [173]. - Selling, general, and administrative expenses increased by $27,000, or 3%, to approximately $878,000 for the three months ended July 31, 2025, mainly due to increased stock compensation expense [195]. - Interest expense rose to $184,000 for the three months ended July 31, 2025, an increase of $161,000 or 715% compared to the same period in 2024 [196]. Accounting and Reporting - No material changes to critical accounting policies and estimates from the 2025 Annual Report on Form 10-K [211]. - Smaller reporting company is not required to provide quantitative and qualitative disclosures about market risk [212].

Core Viewpoint - HeartSciences Inc. is actively engaging with investors through multiple virtual events in August 2025 to showcase its AI-powered ECG technology aimed at early heart disease detection [1][2][3] Group 1: Upcoming Events - The company will host an Investor Webinar on August 20, 2025, at 2:00 PM Eastern Time, providing an overview of its mission, market opportunity, and recent progress [2] - HeartSciences will also present at the Emerging Growth Conference 85 on the same day at 3:10 PM Eastern Time, allowing real-time interaction with investors [3] - Archived webcasts of these events will be available for those unable to attend live [4] Group 2: Company Overview - HeartSciences focuses on enhancing the clinical utility of ECGs through innovative AI technology, aiming to improve cardiac screening, especially in frontline clinical settings [5] - The company possesses one of the largest libraries of AI-ECG algorithms and plans to offer these through a cloud-based solution and a low-cost ECG hardware platform [5] - The MyoVista® wavECG™, the company's first product candidate for FDA clearance, is designed to provide diagnostic information related to cardiac dysfunction alongside conventional ECG data [5]